About Editas Medicine (NASDAQ:EDIT)
Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EDIT
CUSIPN/A
Phone617-401-9000
Debt
Debt-to-Equity Ratio0.16%
Current Ratio9.05%
Quick Ratio9.05%
Price-To-Earnings
Trailing P/E Ratio-11.05
Forward P/E Ratio-9.82
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.73 million
Price / Sales110.70
Cash FlowN/A
Price / CashN/A
Book Value$4.59 per share
Price / Book7.06
Profitability
EPS (Most Recent Fiscal Year)($2.98)
Net Income$-120,320,000.00
Net Margins-876.49%
Return on Equity-61.92%
Return on Assets-32.60%
Miscellaneous
Employees112
Outstanding Shares46,880,000
Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions
What is Editas Medicine's stock symbol?
Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."
How were Editas Medicine's earnings last quarter?
Editas Medicine (NASDAQ:EDIT) issued its quarterly earnings data on Tuesday, March, 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.75) by $0.09. The business earned $3.70 million during the quarter, compared to analysts' expectations of $4.25 million. Editas Medicine had a negative return on equity of 61.92% and a negative net margin of 876.49%. The company's quarterly revenue was up 311.1% on a year-over-year basis. During the same quarter last year, the business posted ($1.10) EPS. View Editas Medicine's Earnings History.
When is Editas Medicine's next earnings date?
What price target have analysts set for EDIT?
9 Wall Street analysts have issued twelve-month target prices for Editas Medicine's stock. Their predictions range from $27.00 to $67.00. On average, they expect Editas Medicine's share price to reach $45.60 in the next twelve months. View Analyst Ratings for Editas Medicine.
What are Wall Street analysts saying about Editas Medicine stock?
Here are some recent quotes from research analysts about Editas Medicine stock:
- 1. According to Zacks Investment Research, "Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. " (3/9/2018)
- 2. Cann analysts commented, "Editas Medicine announced on February 16 the appointment of Jessica Hopfield, Ph.D., to its Board of Directors, effective immediately. Dr. Hopfield is currently the Chairperson of the Board of Trustees of the Joslin Diabetes Center and serves as Lead Independent Director on the Board of Directors of Insulet Corporation. We believe Dr. Hopfield will bring significant commercial and operational experience to the Editas board." (2/16/2018)
Who are some of Editas Medicine's key competitors?
Some companies that are related to Editas Medicine include Bio-Techne (TECH), Spark Therapeutics (ONCE), arGEN-X BV (ARGX), China Biologic Products (CBPO), Halozyme (HALO), CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Sangamo Therapeutics (SGMO), Repligen (RGEN), Acceleron Pharma (XLRN), Momenta Pharmaceuticals (MNTA), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD) and DBV Technologies (DBVT).
Who are Editas Medicine's key executives?
Editas Medicine's management team includes the folowing people:
- Ms. Katrine S. Bosley, CEO, Pres & Director (Age 50)
- Dr. Charles Albright Ph.D., Chief Scientific Officer (Age 60)
- Dr. Gerald Cox M.D., Ph.D., Chief Medical Officer (Age 59)
- Dr. Feng Zhang Ph.D., Co-Founder and Scientific Advisory Board Member
- Dr. George M. Church Ph.D., Co-Founder and Scientific Advisory Board Member (Age 64)
When did Editas Medicine IPO?
(EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.
Has Editas Medicine been receiving favorable news coverage?
Media stories about EDIT stock have been trending positive recently, according to Accern. Accern scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Editas Medicine earned a daily sentiment score of 0.25 on Accern's scale. They also assigned media stories about the company an impact score of 46.46 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of Editas Medicine?
Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Editas Medicine's stock price today?
One share of EDIT stock can currently be purchased for approximately $32.38.
How big of a company is Editas Medicine?
Editas Medicine has a market capitalization of $1.62 billion and generates $13.73 million in revenue each year. The company earns $-120,320,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis. Editas Medicine employs 112 workers across the globe.
How can I contact Editas Medicine?
Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]
MarketBeat Community Rating for Editas Medicine (EDIT)
MarketBeat's community ratings are surveys of what our community members think about Editas Medicine and other stocks. Vote "Outperform" if you believe EDIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDIT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Editas Medicine (NASDAQ:EDIT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for Editas Medicine in the last 12 months. Their average twelve-month price target is $45.60, suggesting that the stock has a possible upside of 40.65%. The high price target for EDIT is $67.00 and the low price target for EDIT is $27.00. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Buy | Hold |
| Consensus Rating Score: | 2.33 | 2.40 | 2.56 | 2.44 |
| Ratings Breakdown: | 1 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
4 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $45.60 | $45.60 | $32.60 | $27.00 |
| Price Target Upside: | 40.65% upside | 10.21% upside | 5.83% downside | 8.00% upside |
Editas Medicine (NASDAQ:EDIT) Consensus Price Target History
Editas Medicine (NASDAQ:EDIT) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Editas Medicine (NASDAQ:EDIT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Editas Medicine (NASDAQ EDIT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 19.40%
Institutional Ownership Percentage: 65.44%
Editas Medicine (NASDAQ EDIT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/2/2018 | Katrine Bosley | Insider | Sell | 8,333 | $32.16 | $267,989.28 | |  |
| 3/20/2018 | Andrew A F Hack | CFO | Sell | 40,000 | $38.06 | $1,522,400.00 | 6,000 | |
| 3/16/2018 | Andrew A F Hack | CFO | Sell | 6,000 | $39.43 | $236,580.00 | 6,000 | |
| 3/9/2018 | Katrine Bosley | Insider | Sell | 9,134 | $45.00 | $411,030.00 | 1,318,631 | |
| 3/1/2018 | Katrine Bosley | Insider | Sell | 8,333 | $35.72 | $297,654.76 | | |
| 2/16/2018 | Andrew A F Hack | CFO | Sell | 18,000 | $34.21 | $615,780.00 | | |
| 2/1/2018 | Katrine Bosley | CEO | Sell | 8,333 | $36.18 | $301,487.94 | 1,338,898 | |
| 1/30/2018 | Katrine Bosley | Insider | Sell | 20,000 | $38.79 | $775,800.00 | 1,354,431 | |
| 1/23/2018 | Katrine Bosley | Insider | Sell | 3,338 | $35.28 | $117,764.64 | 1,364,431 | |
| 1/3/2018 | Katrine Bosley | Insider | Sell | 14,995 | $34.15 | $512,079.25 | | |
| 12/19/2017 | Andrew A F Hack | CFO | Sell | 14,649 | $24.68 | $361,537.32 | 5,000 | |
| 12/15/2017 | Andrew A F Hack | CFO | Sell | 5,000 | $24.31 | $121,550.00 | 5,000 | |
| 12/1/2017 | Katrine Bosley | Insider | Sell | 8,333 | $29.58 | $246,490.14 | 1,387,897 | |
| 11/20/2017 | Andrew A F Hack | CFO | Sell | 5,000 | $25.35 | $126,750.00 | 5,000 | |
| 11/17/2017 | Andrew A F Hack | CFO | Sell | 5,000 | $24.81 | $124,050.00 | 5,000 | |
| 11/1/2017 | Katrine Bosley | Insider | Sell | 8,333 | $23.64 | $196,992.12 | 1,393,322 | |
| 10/2/2017 | Katrine Bosley | Insider | Sell | 8,333 | $24.78 | $206,491.74 | | |
| 9/5/2017 | Katrine Bosley | Insider | Sell | 16,666 | $20.33 | $338,819.78 | 1,414,629 | |
| 9/1/2017 | Katrine Bosley | CEO | Sell | 10,000 | $20.42 | $204,200.00 | 1,414,629 | |
| 8/11/2017 | Katrine Bosley | Insider | Sell | 16,666 | $20.02 | $333,653.32 | 1,431,095 | |
| 6/2/2017 | Boris Nikolic | Director | Buy | 35,000 | $14.07 | $492,450.00 | 35,000 | |
| 6/2/2017 | Gerald Frank Cox | Insider | Buy | 4,000 | $14.15 | $56,600.00 | 4,000 | |
| 5/22/2017 | Kevin Bitterman | Director | Sell | 1,000,000 | $17.00 | $17,000,000.00 | | |
| 3/15/2017 | Alexandra Glucksmann | COO | Sell | 1,000 | $26.41 | $26,410.00 | 118,788 | |
| 2/15/2017 | Alexandra Glucksmann | COO | Sell | 6,000 | $20.58 | $123,480.00 | 123,788 | |
| 2/15/2017 | Andrew A F Hack | CFO | Sell | 3,000 | $19.20 | $57,600.00 | 3,000 | |
| 1/11/2017 | Andrew A F Hack | CFO | Sell | 15,000 | $19.20 | $288,000.00 | 15,000 | |
| 12/7/2016 | Polaris Venture Management Co. | Major Shareholder | Sell | 75,000 | $15.82 | $1,186,500.00 | | |
| 12/6/2016 | Kevin Bitterman | Director | Sell | 130,000 | $15.79 | $2,052,700.00 | | |
| 11/23/2016 | Kevin Bitterman | Director | Sell | 21,480 | $15.71 | $337,450.80 | | |
| 11/22/2016 | Polaris Venture Management Co. | Major Shareholder | Sell | 12,819 | $15.77 | $202,155.63 | | |
| 11/15/2016 | Kevin Bitterman | Director | Sell | 88,900 | $16.96 | $1,507,744.00 | | |
| 9/8/2016 | Polaris Venture Management Co. | Major Shareholder | Sell | 500,000 | $16.80 | $8,400,000.00 | | |
| 9/6/2016 | Kevin P. Starr | Major Shareholder | Sell | 5,890 | $15.90 | $93,651.00 | | |
| 8/23/2016 | Alexandra Glucksmann | COO | Sell | 1,000 | $20.00 | $20,000.00 | 118,788 | |
| 2/8/2016 | James E Flynn | Insider | Buy | 100,000 | $16.00 | $1,600,000.00 | | |
(Data available from 1/1/2013 forward)
Editas Medicine (NASDAQ EDIT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Editas, Millennium vet launches new biotech with $56M from Third Rock
www.bizjournals.com - April 24 at 8:05 AM |
 | Editas Medicine Inc (NASDAQ:EDIT): What Does The Future Look Like?
finance.yahoo.com - April 24 at 8:05 AM |
 | $3.23 Million in Sales Expected for Editas Medicine (EDIT) This Quarter
www.americanbankingnews.com - April 23 at 5:33 AM |
| NanoString Technologies (NSTG) vs. Editas Medicine (EDIT) Financial Comparison
www.americanbankingnews.com - April 23 at 1:50 AM |
| Zacks: Brokerages Anticipate Editas Medicine (EDIT) Will Announce Earnings of -$0.77 Per Share
www.americanbankingnews.com - April 21 at 1:20 AM |
| Editas Medicine (EDIT) Given "Market Perform" Rating by Oppenheimer Analysts
www.americanbankingnews.com - April 17 at 7:01 PM |
| BidaskClub Upgrades Editas Medicine (EDIT) to "Buy"
www.americanbankingnews.com - April 13 at 11:05 AM |
| Editas Medicine (EDIT) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 13 at 1:40 AM |
| Editas Medicine (EDIT) Given "Hold" Rating at Cann
www.americanbankingnews.com - April 11 at 6:13 PM |
| JPMorgan Chase Reiterates "$27.00" Price Target for Editas Medicine (EDIT)
www.americanbankingnews.com - April 11 at 1:19 PM |
| Zacks Investment Research Downgrades Editas Medicine (EDIT) to Sell
www.americanbankingnews.com - April 7 at 3:53 PM |
| Brokerages Anticipate Editas Medicine Inc (EDIT) Will Post Quarterly Sales of $3.23 Million
www.americanbankingnews.com - April 6 at 4:43 AM |
| Editas Medicine (EDIT) Downgraded by ValuEngine
www.americanbankingnews.com - April 5 at 6:52 PM |
| Editas Medicine (EDIT) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - April 5 at 1:57 PM |
| Editas Medicine Inc (EDIT) Insider Katrine Bosley Sells 8,333 Shares
www.americanbankingnews.com - April 4 at 10:56 PM |
| Brokerages Anticipate Editas Medicine Inc (EDIT) Will Announce Earnings of -$0.77 Per Share
www.americanbankingnews.com - April 4 at 3:06 AM |
 | Form 3 Editas Medicine, Inc. For: Mar 27 Filed by: MULLEN JAMES C
www.streetinsider.com - March 30 at 8:27 AM |
| Editas Medicine (EDIT) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - March 29 at 12:34 PM |
| Editas Medicine (EDIT) Names James C. Mullen as Chairman
www.streetinsider.com - March 28 at 5:27 PM |
 | BRIEF-Editas Medicine Names James Mullen As Chairman Of Board
www.reuters.com - March 28 at 5:27 PM |
| Editas Medicine (EDIT) Raised to Buy at SunTrust Banks
www.americanbankingnews.com - March 26 at 8:14 PM |
| Editas Medicine (EDIT) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - March 26 at 2:30 PM |
| Editas Medicine (EDIT) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 24 at 1:54 PM |
| Andrew A. F. Hack Sells 6,000 Shares of Editas Medicine Inc (EDIT) Stock
www.americanbankingnews.com - March 20 at 7:52 PM |
| Insider Selling: Editas Medicine Inc (EDIT) CFO Sells 40,000 Shares of Stock
www.americanbankingnews.com - March 20 at 7:32 PM |
| Editas Medicine Inc (EDIT) Expected to Announce Quarterly Sales of $3.23 Million
www.americanbankingnews.com - March 20 at 8:46 AM |
| Editas Medicine Inc (EDIT) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 19 at 1:52 AM |
| -$0.77 Earnings Per Share Expected for Editas Medicine Inc (EDIT) This Quarter
www.americanbankingnews.com - March 18 at 1:20 AM |
| Editas Medicine (EDIT) PT Raised to $43.00 at Morgan Stanley
www.americanbankingnews.com - March 14 at 11:44 AM |
| BRIEF-Editas Medicine Inc Files For Mixed Shelf Of Up To $150 Million – SEC Filing
www.reuters.com - March 13 at 5:49 PM |
| Insider Selling: Editas Medicine Inc (EDIT) Insider Sells 9,134 Shares of Stock
www.americanbankingnews.com - March 13 at 10:17 AM |
| Zacks Investment Research Upgrades Editas Medicine (EDIT) to Hold
www.americanbankingnews.com - March 9 at 10:14 PM |
| Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno
finance.yahoo.com - March 9 at 9:46 AM |
| Q1 2018 EPS Estimates for Editas Medicine Inc Cut by SunTrust Banks (EDIT)
www.americanbankingnews.com - March 9 at 8:08 AM |
| Q1 2018 Earnings Estimate for Editas Medicine Inc Issued By Oppenheimer (EDIT)
www.americanbankingnews.com - March 9 at 8:05 AM |
 | Editas Medicine Announces Fourth Quarter and Full Year 2017 ... - GlobeNewswire (press release)
globenewswire.com - March 8 at 5:34 PM |
 | Here's Why Editas Medicine Inc. Ticked Up Today - Motley Fool
www.fool.com - March 8 at 5:34 PM |
| Here's Why Editas Medicine Inc. Ticked Up Today
finance.yahoo.com - March 7 at 5:37 PM |
| Here's Why Editas Medicine Inc. Ticked Up Today
finance.yahoo.com - March 7 at 5:37 PM |
| Barclays Boosts Editas Medicine (EDIT) Price Target to $46.00
www.americanbankingnews.com - March 7 at 4:42 PM |
| Editas Medicine (EDIT) Given New $67.00 Price Target at JMP Securities
www.americanbankingnews.com - March 7 at 4:38 PM |
| Editas Medicine (EDIT) Posts Earnings Results, Misses Estimates By $0.09 EPS
www.americanbankingnews.com - March 6 at 9:12 PM |
| Editas Medicine Q4 Earnings Preview
finance.yahoo.com - March 6 at 5:22 PM |
| Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update
finance.yahoo.com - March 6 at 5:22 PM |
| Editas Medicine, Inc. to Host Earnings Call
finance.yahoo.com - March 6 at 5:22 PM |
| Critical Analysis: OpGen (OPGN) and Editas Medicine (EDIT)
www.americanbankingnews.com - March 6 at 11:34 AM |
| Katrine Bosley Sells 8,333 Shares of Editas Medicine Inc (EDIT) Stock
www.americanbankingnews.com - March 5 at 7:00 PM |
| Arrowstreet Capital Limited Partnership Grows Position in Editas Medicine Inc (EDIT)
www.americanbankingnews.com - March 4 at 4:32 AM |
| Hudson Bay Capital Management LP Has $1.84 Million Stake in Editas Medicine Inc (EDIT)
www.americanbankingnews.com - March 2 at 12:49 PM |
| Pentagon Lab Worries About CRISPR Bioattack As China Seeks Genome Lead
finance.yahoo.com - March 1 at 5:36 PM |
Editas Medicine (NASDAQ:EDIT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Editas Medicine (NASDAQ:EDIT) Income Statement, Balance Sheet and Cash Flow Statement
Editas Medicine (NASDAQ EDIT) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
